Oxaliplatin: Preclinical perspectives on the mechanisms of action, response and resistance

ecancermedicalscience

Volumn 3, Issue 1, 2009, Pages

  Seetharam, R N ^a   Sood, A ^a   Goel, S ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; COLORECTAL CANCER; DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EXCISION REPAIR; METASTASIS; MISMATCH REPAIR; SHORT SURVEY;

EID: 77956050458     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2009.153     Document Type: Short Survey

References (47)

1. Cancer Facts & Figures - 2009, American Cancer Society (ACS), Atlanta, Georgia, 2009 (http://seer.cancer.gov/csr/1975-2006/results-single/ sect-01-table.01.pdf).
2. Lebwohl D, Canetta R: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998, 34:1522-1534.
3. Martin LP, Hamilton TC, Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14:1291-1295.
4. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 2005, 352:476-487.
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
6. Armand JP, Boige V, Raymond E, Fizazi K, Faivre S, Ducreux M: Oxaliplatin in colorectal cancer: an overview. Semin Oncol 2000, 27:96-104.
7. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52:1855-1865.
8. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L: In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001, 48:398-406.
9. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P: Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998, 54:770-777.
10. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000, 58:920-927.
11. Scheeff ED, Briggs JM, Howell SB: Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 1999, 56:633-643.
12. Wu Y, Pradhan P, Havener J, Boysen G, Swenberg JA, Campbell SL, Chaney SG: NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J Mol Biol 2004, 341:1251-1269.
13. Gelasco A, Lippard SJ: NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 1998, 37:9230-9239.
14. Johnson NP, Hoeschele JD, Rahn RO: Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 1980, 30:151-169.
15. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J: Adducts of the antitumour drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 1985, 24:707-713.
16. Zwelling LA, Anderson T, Kohn KW: DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979, 39:365-369.
17. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998, 9:1053-1071.
18. Gibbons GR, Page JD, Mauldin SK, Husain I, Chaney SG: Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res 1990, 50:6497-6501.
19. Chaney SG, Campbell SL, Bassett E, Wu Y: Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005, 53:3-11.
20. Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG: Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol 2007, 373:1123-1140.
21. Farrell NP: Preclinical perspectives on the use of platinum compounds in cancer chemotherapy. Semin Oncol 2004, 31:1-9.
22. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P: Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003, 3:21-29.
23. Koberle B, Masters JR, Hartley JA, Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999, 9:273-276.
24. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B: Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumour cell lines. Int J Cancer 2004, 110:352-361.
25. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
26. Sancar A: DNA excision repair. Annu Rev Biochem 1996, 65:43-81.
27. Petit C, Sancar A: Nucleotide excision repair: from E. coli to man. Biochimie 1999, 81:15-25.
28. Altaha R, Liang X, Yu JJ, Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004, 14:959-970.
29. Park CH, Bessho T, Matsunaga T, Sancar A: Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 1995, 270:22657-22660.
30. Biggerstaff M, Szymkowski DE, Wood RD: Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro. Embo J 1993, 12:3685-3692.
31. Gillet LC, Scharer OD: Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006, 106:253-276.
32. Reardon JT, Sancar A: Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol 2005, 79:183-235.
33. Costa RM, Chigancas V, Galhardo Rda S, Carvalho H, Menck CF: The eukaryotic nucleotide excision repair pathway. Biochimie 2003, 85:1083-1099.
34. Park CJ, Choi BS: The protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway. Febs J 2006, 273:1600-1608.
35. van Hoffen A, Balajee AS, van Zeeland AA, Mullenders LH: Nucleotide excision repair and its interplay with transcription. Toxicology 2003, 193:79-90.
36. Bergstralh DT, Sekelsky J: Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 2008, 24:70-76.
37. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998, 24:331-344.
38. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293-2297.
39. Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P: Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs 2001, 12:741-751.
40. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005, 327:225-233.
41. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003, 39:112-119.
42. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C, Johnston PG: Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 2006, 66:2765-2777.
43. Gossage L, Madhusudan S: Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007, 33:565-577.
44. Martinez-Balibrea E, Plasencia C, Gines A, Martinez-Cardus A, Musulen E, et al. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther 2009, 8:771-778.
45. Gourdier I, Del Rio M, Crabbe L, Candeil L, Copois V ewt al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 2002, 529:232-236.
46. Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S: Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 2009, 9:3.
47. Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB: cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 2005, 55:1-11.